Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: Indications and modalities

Diabetes and Metabolism

Volumn 32, Issue 1, 2006, Pages 7-13

  Monnier, L ^a   Colette, C ^b  

^a LAPEYRONIE HOSPITAL   (France)

^b NONE

Author keywords

Rapid acting insulin; Regimens; Timing; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; GLULISINE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LONG ACTING INSULIN; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; INSULIN; INSULIN, NEUTRAL;

ADD ON THERAPY; CLINICAL TRIAL; DIABETES CONTROL; DIETARY INTAKE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; MEAL; MEDICAL CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHYSICIAN; POSTPRANDIAL STATE; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; BLOOD; DRUG ADMINISTRATION; DRUG COMBINATION; MEDICAL SOCIETY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; POSTPRANDIAL PERIOD; SOCIETIES, MEDICAL;

EID: 33646110527     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70241-0     Document Type: Review

References (48)

1. UKPDS. Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years (UKPDS 13). BMJ 1995;310:83-8
2. Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Smith DG. Risk factors for diabetic peripheral sensory neuropathy. Results of the Seattle Prospective Diabetic Foot Study. Diabetes Care 1997;20:1162-7
3. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995;18:258-68
4. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 1996;27:63-8
5. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 1998;316:823-8
6. Standl E, Balletshofer B, Dahl B, et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996;39:1540-5
7. Groeneveld Y, Petri H, Hermans J, Springer MP. Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review. Diabet Med 1999;16:2-13
8. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998;21:1167-72
9. Knuiman MW, Welborn TA, Whittall DE. An analysis of excess mortality rates for persons with non-insulin-dependent diabetes mellitus in Western Australia using the Cox proportional hazards regression model. Am J Epidemiol 1992;135:638-48
10. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-83
11. Stratton I, Adler A, Neil A, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
12. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28 (Suppl 1):S4-S36
13. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. Endocr Pract 2002;8 (Suppl 1):5-11
14. IDF. (International Diabetes Federation) A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med 1999;16:716-30
15. Monnier L, Grimaldi A, Charbonnel B, et al. Management of French patients with type 2 diabetes mellitus in medical general practice: Report of the Mediab observatory. Diabetes Metab 2004;30:35-42
16. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999;22:403-8
17. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
18. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6
19. Cryer P. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999;15:42-6
20. Riddle M. Timely addition of insulin to oral therapy for Type 2 diabetes. Diabetes Care 2002;25:395-6
21. Riddle MC, Rosenstock J, Gerich J, on behalf of the Insulin Glargine 4002 Study Investigators. The treat - to - target trial. Randomized addition of Glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
22. Ryysy L, Yki-Järvinen H, Hänninen J, et al. Simplifying treat to target - the LANMET study. Diabetologia 2004;47 (Suppl 1): A271-2 [Abstract].
23. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care, 2001;24:758-67
24. Yki-Järvinen H, Dressler A, Ziemen M and the HOE: 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bed-time NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-6
25. Bastyr EJ, Stuart CA, Brodows RG, et al, for the IOEZ Study Group. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care 2000;23:1237-41
26. Poulsen MK, Henriksen JE, Hother-Nielsen O, Beck-Nielsen H. The combined effect of a triple therapy with Rosiglitazone, Metformin, and insulin Aspart in type 2 diabertic patients. Diabetes Care 2003;26:3273-9
27. Raskin P, Allen E, Hollander P, et al, for the INITIATE Study Group. Initiating insulin therapy in type 2 diabetes. Diabetes Care 2005;28:260-5
28. Schreiber S, Schneider K, Schweitzer MA. The efficacy of long-term insulin glargine and oral antidiabetic therapy in patients with type 2 diabetes. Diabetes 2005;54 (Suppl 1) :A143
29. Hirsh IB. Insulin analogues. N Engl J Med 2005;352:174-83
30. Monnier L, Colette C, Rabasa-Lhoret R, et al. Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 2002;25:737-41
31. Owens D, Zinman B, Bolli G. Insulins today and beyond. Lancet 2001;358:739-46
32. Lee W, Zinman B. From insulin to insulin analogs: progress in the treatment of type 1 diabetes. Diabetes Rev 1998;6:73-88
33. Monnier L, Lapinski H, Colette C. Contributions of fasting and post-prandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003;26:881-5
34. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premix insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254-9
35. Rubio Terres C, Rodriguez J, Bolinder B, De Pablos P. Pharmacoeconomic analysis of insulin glargine compared with NPH insulin in patients with type 2 diabetes in Spain [Abstract] Diabetes 2004;52(Suppl 2):A291
36. Dailey G, JR, Moses R, Ways K. Glycemic control with insulin glulisine versus regular human insulin in a basal-bolus regimen in patients with type 2 diabetes [Abstract]. Diabetes 2004;52 (Suppl 2):A121 [Abstract 514-P]
37. Monnier L, Benichou M, Charra-Ebrard S, Boegner C, Colette C. An overview of the rationale for therapeutic strategies in Type 2 diabetes: from the evidence to new perspectives. Diabetes Metab 2005;31:101-9
38. Monnier L, Colette C, Lapinski H. Global assessment for quality and control in type 2 diabetic patients. Eur J Clin Invest 2004;34:37-42
39. Monnier L, Colette C. Should seven be the magic number of type 2 diabetes? Diabetologia 2005;48:1943-4
40. Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract 1999;43:137-42
41. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984;7:188-99
42. Ristic S, Bates PC. Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus. Diabetes Technol Ther 2003;5:57-66
43. Skrha J, Smahelova A, Andel M, et al. Insulin lispro improves post-prandial glucose control in patients with diabetes mellitus. Sb Lek 2002;103:15-21
44. Hartemann-Heurtier A, Sachon C, Masseboeuf N, Corset E, Grimaldi A. Functional intensified insulin therapy with short-acting insulin analog: effects on HbA1c and frequency of severe hypoglycemia. An observational cohort study. Diabetes Metab 2003;29:53-7
45. Chapman TM, Noble S, Goa KL. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2002;62:1945-81
46. Rosenstock J, Wyne K. Insulin treatment in type 2 diabetes. In Goldstein B, Müller-Wieland D, eds. Textbook of Type 2 Diabetes, London: Martin Dunitz 2003;131-54
47. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994;43:396-402
48. Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999;55:199-203